Role of Long-Acting Injectable Second-Generation Antipsychotics in the Treatment of First-Episode Schizophrenia: A Clinical Perspective
Approximately 80% of patients with the first-episode schizophrenia reach symptomatic remission after antipsychotic therapy. However, within two years most of them relapse, mainly due to low levels of insight into the illness and nonadherence to their oral medication. Therefore, although the formal d...
Main Authors: | Radovan Přikryl, Hana Přikrylová Kučerová, Michaela Vrzalová, Eva Češková |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2012-01-01
|
Series: | Schizophrenia Research and Treatment |
Online Access: | http://dx.doi.org/10.1155/2012/764769 |
Similar Items
-
Long-Acting Injectable Antipsychotics in First-Episode Schizophrenia
by: Eduard Parellada, et al.
Published: (2012-01-01) -
Long-Acting Injectable Antipsychotics for First-Episode Schizophrenia: The Pros and Cons
by: Borah Kim, et al.
Published: (2012-01-01) -
Withdrawal related adverse effects of antipsychotic medication in a patient with first-episode schizophrenia
by: Barteček Richard, et al.
Published: (2011-10-01) -
The Use of Long-Acting Injectable Antipsychotic Therapy for Schizophrenia
by: Jason Jiang, et al.
Published: (2018-09-01) -
Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life
by: Montemagni C, et al.
Published: (2016-04-01)